Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $14.65 USD
Change Today -0.82 / -5.30%
Volume 308.4K
HRTX On Other Exchanges
As of 1:29 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

heron therapeutics inc (HRTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $15.86
52 Week Low
10/13/14 - $6.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

heron therapeutics inc (HRTX) Related Businessweek News

No Related Businessweek News Found

heron therapeutics inc (HRTX) Details

Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform. The company's drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients. Its lead product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. The company's product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.

47 Employees
Last Reported Date: 03/7/14
Founded in 1983

heron therapeutics inc (HRTX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $349.3K
President and Director
Total Annual Compensation: $453.8K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $52.6K
Compensation as of Fiscal Year 2013.

heron therapeutics inc (HRTX) Key Developments

Heron Therapeutics Initiates Phase 1 Clinical Study of HTX-011 for the Treatment of Post-Operative Pain

Heron Therapeutics, Inc. announced the initiation of a Phase 1 clinical trial of HTX-011, which is being developed for the treatment of post-operative pain. HTX-011 utilizes the Companyâ s proprietary Biochronomer® polymer-based drug delivery platform to release the local anesthetic bupivacaine and the anti-inflammatory meloxicam over an extended period. The single-ascending dose, placebo-controlled study in healthy volunteers will evaluate safety, pharmacokinetics, and pharmacodynamics of the anesthetic effects of the product. HTX-011 has previously been shown to significantly reduce pain in a validated animal model for up to 72 hours following surgery. The company look forward to rapidly completing its Phase 1 study of HTX-011, the lead product candidate in post-surgical pain program, and expect to report initial results before the end of the first quarter of 2015.

Heron Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 08:50 AM

Heron Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 08:50 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Barry D. Quart, Chief Executive Officer and Director.

Heron Therapeutics, Inc. Announces Resignation of Mark S. Gelder as Senior Vice President and Chief Medical Officer

On January 11, 2015, Mark S. Gelder, M.D. notified Heron Therapeutics, Inc. that he would be resigning as the Company's Senior Vice President and Chief Medical Officer for personal reasons. Dr. Gelder will remain with the Company until January 23, 2015 to assist in transitioning his duties and responsibilities. Dr. Gelders responsibilities are being appropriately transitioned and the Company believes his departure will not affect the timing of any of the Company's activities in which he is involved.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HRTX:US $14.65 USD -0.82

HRTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $68.32 USD -2.90
Foamix Pharmaceuticals Ltd $9.17 USD -0.08
Johnson & Johnson $100.20 USD -2.32
Pacira Pharmaceuticals Inc/DE $95.70 USD -2.70
Sanofi €87.65 EUR -0.19
View Industry Companies

Industry Analysis


Industry Average

Valuation HRTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HERON THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at